Targets › TOPO2
2 programs from 1 company in 4 trials: 3 Phase 2, 1 Phase 3; Oncology; next expected readout Feb 2027.
Open in Phaseline: the race on TOPO2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Centre Hospitalier Universitaire Dijon | modified FOLFOX Multi-drug chemotherapy: folate antagonist (folinic acid), thymidylate synthase inhibitor | TOPO2, TYMS, DHFR, SLC22A16 | Phase 3 | Colon Cancer; Locally Advanced or Metastatic Small Bowel Adenocarcinoma | Feb 2027 |
| Centre Hospitalier Universitaire Dijon | FOLFOXIRI Protocol (modified FOLFIRINOX) Combination chemotherapy: irinotecan (TOPO1 inhibitor) + oxaliplatin (TOPO2 inhibitor) + f | TOPO1, TOPO2, TYMS | Phase 2 | Locally Advanced or Metastatic Small Bowel Adenocarcinoma; Neuroendocrine Carcinoma | Feb 2027 |
Locally Advanced or Metastatic Small Bowel Adenocarcinoma (2) Neuroendocrine Carcinoma (1) Colon Cancer (1)
small molecule (2)
Centre Hospitalier Universitaire Dijon (2)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.